Enhancing Bone Healing Through Localized Cold Therapy in a Murine Femoral Fracture Model

Abstract

Fracture healing, a critical and complex biological process, often presents challenges in clinical practice with the current standards failing to fully address the medical needs for rapid and effective recovery. In this work, a localized cold therapy is investigated as an alternative approach to expedite bone healing. We hypothesized that optimized cold application can enhance bone healing within a fracture model by inducing hypoxia, leading to accelerated angiogenesis along with improved osteogenesis. A short, localized cold exposure is directly applied to the fracture site over a 4-week period in a mouse fracture model, aiming to assess its impact on bone formation through mechanisms of angiogenesis and osteogenesis. Our results revealed a significantly greater volume of new bone tissue and enhanced vascularity at the fracture site in the cold-treated group compared with controls. Calcified tissue histology analysis showed that the accelerated callus maturation and development of the vascular network following cold exposure were associated with an activity increase of alkaline phosphatase and transient receptor potential vanilloid 1. These biological changes were accompanied by a hypoxic environment induced during cold therapy. The study provides compelling evidence supporting the efficacy of intermittent cold therapy in accelerating fracture healing. These promising results highlight the need for further research in larger-scale studies and diverse fracture models, underlining the potential of cold therapy as a novel, noninvasive treatment strategy in orthopedic care.

Impact Statement

Both patients and surgeons desire a nonsurgical option to stimulate bone healing and as a bone growth stimulator, cold therapy is less invasive and less expensive than grafts and chemical therapies, and it potentially reduces pain at the healing site decreasing the need for addictive painkiller prescriptions. Cold therapy has relatively low barriers to regulatory approval at FDA [Class 2 device with prior art (510K)], like other devices using mild to medium cold for physical medicine applications.